

NATIONAL BOARD OF TRUSTEES

John P. Butler
Chair

Gail S. Wick, MHSA, BSN, RN, CNN
Chair-Elect

Timothy G. Morgan
Immediate Past Chair

Orlando M. Gutiérrez, MD, MMSc
Chair, Medical Affairs

Robert M. Tarola, CPA
Treasurer

John F. Weidenbruch, Esq.
Secretary

Akhtar Ashfaq, MD, FACP, FASN

Douglas A. Asofsky

Alfreda Bradley-Coar

Steven G. Elliott, PhD

Stephen M. Gansler

Dalal J. Haldeman, MBA, PhD

Jerry D. Klepner

Nora V. Lee

Alan B. Leichtman, MD

Robert B. Lewis, III

Rulan S. Parekh, MD, MS

Frank D. Pelliccione

Jennifer E. Robinson

H. Jerome Russell

Charlotte E. Sibley

Rashaan W. Thompson, Esq.

LaVarne A. Burton
President & CEO, ex-officio

June 1, 2020

Chairman Scott Lipps
77 South High Street
Columbus, OH 43215

Dear Chairman Lipps,

On behalf of the American Kidney Fund, including the 26,062 Ohio citizens currently living with end-stage-renal disease, we are writing to respectfully ask for your support of House Bill 469, which would require any carrier issuing a health plan to count any payments made by a person or on a person's behalf when calculating the enrollee's overall contribution to any out-of-pocket maximum or any cost-sharing requirement under the carrier's health plan.

The American Kidney Fund (AKF), based in Rockville, Maryland is the nation's leading nonprofit organizations working on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease, from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. We are also one of the nation's top-rated nonprofits, investing 97 cents of every donated dollar in programs, AKF has also received the highest 4-Star rating from Charity Navigator for 18 consecutive years, as well as the Platinum Seal of Transparency from Guidestar.

Due to high cost-sharing requirements and the expensive cost of prescription medications, many patients with chronic and rare diseases depend on financial assistance for their specialty medications. Recently, healthplans have been instituting a practice where copayment assistance is no longer counted towards their out-of-pocket cost limits. Known as accumulator programs, this practice coupled with the rise of high deductible health plans makes it difficult, if not impossible, for patients to adhere to their treatment plan.

Many of these plan changes have also been implemented with little to no notification to the member. Patients may not be aware of the change in their plan until they arrive at the pharmacy to pick up their prescription and find out that they must pay for the full cost of the drug. Often times, patients walk away without their needed medication because they simply can not afford to pay. For those patients that do receive notification, the language can be difficult to understand, even for the most seasoned of healthcare experts. Further, some notifications mislead patients into believing that they will be protected when in fact they are not.

This bill seeks to address the issues above and would provide essential protections to ensure patients can both afford and stay stable on their medications. We ask for your support on HB 469.

Thank you in advance for your time and for your consideration of this important issue. If you have any questions or would like any additional information please do not hesitate to contact me directly at mkahn@kidneyfund.org.

Sincerely,



Melanie Lynn Kahn
Director, State Policy and Advocacy
American Kidney Fund

Cc:

Rep. Manning
Rep. Antani
Rep. Butler
Rep. Carruthers
Rep. Ginter
Rep. Grendell
Rep. Holmes
Rep. Keller
Rep. LaTourette
Rep. Plummer
Rep. Swearingen
Rep. Boyd
Rep. Clites
Rep. Lepore-Hagan
Rep. Liston
Rep. Russo
Rep. Upchurch
Rep. West